Coverage
-
October 01, 2013
A New Jersey federal judge on Tuesday approved a $688 million settlement to settle claims that Merck & Co. Inc. and its subsidiary Schering-Plough Corp. concealed test results on the efficacy of their anti-cholesterol drug Vytorin, while also awarding $140 million in attorneys' fees.
2 other articles on this case.
View all »